Trials / Completed
CompletedNCT00076388
Iressa Versus Docetaxel (Taxotere)
A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic Recurrent Non-Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,440 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the effects of ZD1839 or docetaxel in patients with advanced non-small cell lung cancer (NSCLC) that has recurred or progressed after receiving prior treatment with platinum-based chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gefitinib | |
| DRUG | Docetaxel |
Timeline
- Start date
- 2004-02-01
- Primary completion
- 2007-03-01
- Completion
- 2007-10-01
- First posted
- 2004-01-23
- Last updated
- 2011-05-13
Locations
162 sites across 25 countries: United States, Argentina, Belgium, Brazil, Canada, China, Croatia, Denmark, Estonia, France, Germany, Hong Kong, Indonesia, Italy, Latvia, Malaysia, Mexico, Philippines, Singapore, Slovenia, Spain, Sweden, Switzerland, Thailand, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00076388. Inclusion in this directory is not an endorsement.